| 1 |
Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms |
|
| | Pawel Petryszyn,Aleksandra Staniak,Agnieszka Wolosianska,Pawel Ekk-Cierniakowski | | | European Journal of Gastroenterology & Hepatology. 2019; : 1 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? |
|
| | Eamonn M. M. Quigley | | | Therapeutic Advances in Gastroenterology. 2016; 9(2): 199 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis |
|
| | Hossam M. Elsaadany,Mohammed F. Almaghraby,Awatif A. Edrees,Yasser M. Elsherbiny,Roobina K. Kumar | | | The Egyptian Journal of Internal Medicine. 2016; 28(1): 21 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Recent advances in the diagnosis of irritable bowel syndrome |
|
| | Magdy El-Salhy | | | Expert Review of Gastroenterology & Hepatology. 2015; 9(9): 1161 | | | [Pubmed] [Google Scholar] [DOI] | |
|
